Results posted and trading again. More detail than The Age, but boil it down and the article was pretty well on the mark. Extract from the announcement: "The company is aware that the results of the Pentrys trials were the subject of an article published in The Age today. The directors consider that the article is misleading and are concerned that mischievous motives were behind its publication. Needless to say, the company is disappointed by the publication of the article. The trial results were extensive and required comprehensive and time consuming analysis to enable the company to provide an accurate report of the results. Although the analysis suggests further clinical investigation of the current Pentrys formulation does not seem warranted at the present time, the immune and PSA responses observed are intriguing, and additional studies in animal models could lead to clinically useful mechanisms. The company, with its new partner, Hawaii Biotech, Inc., will be considering other clinical trials possibilities, involving the use of the potent immunostimulating adjuvant, GPI-0100."
Pezz
ACU Price at posting:
0.0¢ Sentiment: Buy Disclosure: Not Held
